Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (231-240 of 437) with videos related to

Pageof 44
Sort By:
Targeted Oncology|July 14, 2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 StudyMaya Gottfried, Jaafar Bennouna, Igor Bondarenko, et al.
JAMA Oncology|February 16, 2023
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical TrialsMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trialCesare Gridelli, Eckhard Kaukel, Vanessa Gregorc, et al.
Translational Lung Cancer Research|June 24, 2021
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsiesPetros Christopoulos, Steffen Dietz, Arlou K Angeles, et al.
Genes, Chromosomes & Cancer|February 28, 2023
Real-world data for precision cancer medicine-A European perspectivePetros Christopoulos, Richard Schlenk, Daniel Kazdal, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Pageof 44

Showing results (231-240 of 437) with videos related to

Sort By:
Pageof 44
Targeted Oncology|July 14, 2017
Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 StudyMaya Gottfried, Jaafar Bennouna, Igor Bondarenko, et al.
JAMA Oncology|February 16, 2023
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical TrialsMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trialCesare Gridelli, Eckhard Kaukel, Vanessa Gregorc, et al.
Translational Lung Cancer Research|June 24, 2021
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsiesPetros Christopoulos, Steffen Dietz, Arlou K Angeles, et al.
Genes, Chromosomes & Cancer|February 28, 2023
Real-world data for precision cancer medicine-A European perspectivePetros Christopoulos, Richard Schlenk, Daniel Kazdal, et al.
Lung Cancer (Amsterdam, Netherlands)|January 22, 2016
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung CancerGerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, et al.
The Oncologist|February 14, 2018
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung CancerJoachim von Pawel, David R Spigel, Thomas Ervin, et al.
Cancer Chemotherapy and Pharmacology|May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancerEgbert F Smit, Edward B Garon, Martin Reck, et al.
Future Oncology (London, England)|May 22, 2023
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLCHelena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, et al.
The Lancet. Oncology|January 14, 2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Rolf Kaiser, Anders Mellemgaard, et al.
Pageof 44